{
  "kind": "treatment",
  "slug": "selegiline-eldepryl",
  "type": "medication",
  "name": "Selegiline",
  "summary": "Selegiline (Eldepryl) is a selective MAO-B inhibitor used to treat Parkinson's disease and major depressive disorder.",
  "description": "Selegiline, marketed under brand names including Eldepryl and Zelapar, is a selective, irreversible monoamine oxidase B (MAO-B) inhibitor. At recommended doses, it reduces dopamine breakdown in the brain, thereby enhancing dopaminergic activity. It is indicated as an adjunct to levodopa/carbidopa in Parkinson's disease to reduce 'wearing-off' symptoms, and in transdermal form for the treatment of major depressive disorder. At higher doses, it loses selectivity and inhibits MAO-A as well, increasing the risk of dietary tyramine interactions.",
  "category": "medications/neurology",
  "tags": [
    "MAO-B inhibitor",
    "Parkinson's disease",
    "depression",
    "dopaminergic therapy"
  ],
  "metadata": {
    "drug_classes": [
      "MAO-B inhibitor",
      "Antiparkinsonian agent",
      "Antidepressant"
    ],
    "therapeutic_categories": [
      "Neurology",
      "Psychiatry"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Oral",
      "Patch"
    ],
    "prescription_status": "Prescription only",
    "controlled_substance": false,
    "generic_available": true,
    "brand_names": [
      "Eldepryl",
      "Zelapar",
      "Emsam"
    ],
    "age_groups": [
      "Adult",
      "Geriatric"
    ],
    "treatment_duration": [
      "Long-term maintenance"
    ],
    "specialty_areas": [
      "Neurology",
      "Psychiatry",
      "Movement disorders"
    ],
    "fda_approval_year": 1989
  },
  "clinical_metadata": {
    "primary_indications": [
      "Other",
      "Depression"
    ],
    "off_label_uses": [
      "Atypical depression",
      "Treatment-resistant depression"
    ],
    "contraindications": [
      "Concomitant use with other MAO inhibitors",
      "Concomitant use with meperidine, tramadol, methadone, propoxyphene, or other serotonergic opioids",
      "Pheochromocytoma",
      "Hypersensitivity to selegiline or formulation components"
    ],
    "monitoring_required": [
      "Motor symptoms in Parkinson's disease",
      "Blood pressure (risk of hypertension)",
      "Neuropsychiatric status",
      "Signs of serotonin syndrome if combined with serotonergic drugs"
    ],
    "efficacy_rating": {
      "Parkinson's adjunct therapy": 3,
      "Depression (transdermal)": 3
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "selegiline",
      "Eldepryl",
      "Zelapar",
      "Emsam",
      "MAO-B inhibitor"
    ],
    "synonyms": [
      "L-deprenyl",
      "selegiline hydrochloride"
    ],
    "common_misspellings": [
      "seligiline",
      "selegeline",
      "selegelin"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Adjunctive treatment to levodopa/carbidopa in Parkinson's disease",
        "Major depressive disorder (transdermal form)"
      ]
    },
    {
      "type": "mechanism",
      "text": "Selectively and irreversibly inhibits monoamine oxidase B (MAO-B), reducing dopamine breakdown and increasing dopaminergic activity in the brain; at higher doses, also inhibits MAO-A."
    },
    {
      "type": "dosing",
      "adult": {
        "oral": "Parkinson's disease: 5 mg twice daily with breakfast and lunch; maximum 10 mg/day.",
        "transdermal": "Depression: Start at 6 mg/24 hours; may increase to 9 mg/24 hours or 12 mg/24 hours at intervals of at least 2 weeks."
      },
      "pediatric": {
        "oral": "Not established.",
        "transdermal": "Not established."
      }
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: 5 mg",
        "Orally disintegrating tablets: 1.25 mg, 2.5 mg",
        "Transdermal patches: 6 mg/24 hr, 9 mg/24 hr, 12 mg/24 hr"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Parkinson's motor improvement may be seen within days to weeks; antidepressant effects may take 4â€“6 weeks."
    },
    {
      "type": "adverse_effects",
      "common": [
        "insomnia",
        "nausea",
        "orthostatic hypotension",
        "hallucinations",
        "dry mouth"
      ],
      "less_common": [
        "dyskinesia",
        "confusion",
        "agitation",
        "rash (transdermal)"
      ],
      "serious": [
        "hypertensive crisis (with tyramine-rich foods at higher doses)",
        "serotonin syndrome",
        "hallucinations/psychosis"
      ]
    },
    {
      "type": "warnings",
      "other": [
        "Risk of hypertensive crisis with high dietary tyramine intake at higher or nonselective doses",
        "Avoid concomitant serotonergic drugs due to serotonin syndrome risk",
        "May exacerbate psychiatric symptoms in susceptible individuals",
        "Use caution in hepatic impairment"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "SSRIs/SNRIs",
          "risk": "Serotonin syndrome",
          "action": "Avoid or allow adequate washout period"
        },
        {
          "with": "Tyramine-rich foods (high doses)",
          "risk": "Hypertensive crisis",
          "action": "Advise dietary restrictions at high doses"
        },
        {
          "with": "Opioids (meperidine, tramadol, methadone)",
          "risk": "Serotonin syndrome",
          "action": "Contraindicated"
        },
        {
          "with": "Other MAO inhibitors",
          "risk": "Severe hypertension or serotonin syndrome",
          "action": "Avoid combination"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Motor symptom control and 'off' time in Parkinson's disease",
        "Blood pressure",
        "Neuropsychiatric status",
        "Signs of serotonin syndrome"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Limited human data; use only if benefit outweighs potential risk",
      "lactation": "Unknown if excreted in human milk; caution advised",
      "geriatrics": "Monitor for increased sensitivity to orthostatic hypotension and CNS effects"
    },
    {
      "type": "tapering",
      "text": "May be discontinued without taper at low doses; gradual reduction may be considered to minimize symptom rebound."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Oral form used in Parkinson's disease is selective for MAO-B at recommended doses",
        "Transdermal form approved for major depression in the U.S.",
        "Minimal dietary restrictions at Parkinson's doses; dietary tyramine restriction required for higher antidepressant doses"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Eldepryl Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "NHS - Selegiline",
          "url": "https://www.nhs.uk/medicines/selegiline/"
        },
        {
          "label": "PubChem - Selegiline",
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/Selegiline"
        }
      ]
    }
  ],
  "seo": {
    "title": "Selegiline (Eldepryl) - Uses, Dosage, Side Effects, and Warnings",
    "description": "Selegiline (Eldepryl) is a selective MAO-B inhibitor for Parkinson's disease and depression. Learn about dosing, interactions, and safety precautions."
  }
}
